Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 4, 2007, Pages 291-301

  Enomoto, T ^a   Noda, Yukihiro ^a,b   Nabeshima, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Behavior; Genetic animals; Phencyclidine; Schizophrenia

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPRAZOLAM; AMPHETAMINE; BLONANSERIN; CALCINEURIN; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYCLOSERINE; DESIPRAMINE; DIAZEPAM; GLUTAMIC ACID; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; LYSOPHOSPHATIDIC ACID RECEPTOR; METHADONE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NALOXONE; NEU DIFFERENTIATION FACTOR; OLANZAPINE; PEROSPIRONE; PHENCYCLIDINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; UNINDEXED DRUG;

COGNITIVE DEFECT; DOSE RESPONSE; DRUG ANTAGONISM; FORCED SWIMMING TEST; GENETIC MODEL; LOCOMOTION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SOCIAL INTERACTION; SOCIOPATHY;

ANIMALS; BEHAVIOR, ANIMAL; CALCINEURIN; COGNITION; DISEASE MODELS, ANIMAL; GAIT; GLUTAMIC ACID; HUMANS; INHIBITION (PSYCHOLOGY); MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PHENCYCLIDINE; RECEPTORS, LYSOPHOSPHATIDIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 34547634946     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2007.29.4.1075358     Document Type: Review

References (106)

1. Javitt, D.C., Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148: 1301-8.
2. Krystal, J.H., Karper, L.P., Seibyl, J.P. et al. Subanesthetic effects of the noncompetitive NMDA antagonist ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 1994, 51: 199-214.
3. Malhotra, A.K., Pinals, D.A., Weingartner, H. et al. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996, 14: 301-7.
4. Newcomer, J.W., Farber, N.B., Jevtovic-Todorovic, V. et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20: 106-18.
5. Lahti, A.C., Koffel, B., LaPorte, D., Tamminga, C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13: 9-19.
6. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W., Holzmuller, B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20: 379-82.
7. Carlsson, M., Carlsson, A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989, 75: 221-6.
8. Carlsson, A., Hansson, L.O., Waters, N., Carlsson, M.L. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. Life Sci 1997, 61: 75-94.
9. Nilsson, M., Carlsson, A., Carlsson, M.L. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. J Neural Transm 1997, 104: 1195-205.
10. Carlsson, A., Hansson, L.O., Waters, N., Carlsson, M.L. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl 1999, 174: 2-6.
11. Jentsch, J.D., Roth, R.H. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20: 201-25.
12. Rainey, J.M., Crowder, M.K. Prolonged psychosis attributed to phencyclidine: Report of three cases. Am J Psychiatry 1975, 132: 1076-8.
13. Allen, R.M., Young, S.J. Phencyclidine-induced psychosis. Am J Psychiatry 1978, 135: 1081-4.
14. Gainetdinov, R.R., Mohn, A.R., Caron, M.G. Genetic animal models: Focus on schizophrenia. Trends Neurosci 2001, 24: 527-33.
15. Segal, D.S., Geyer M.A., Schuckit, M.A. Stimulant-induced psychosis: An evaluation of animal models. Essays Neurochem Neuropharmacol 1981, 5: 95-129.
16. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1: 179-86.
17. Sturgeon, R.D., Fessler, R.G., Meltzer, H.Y. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 1979, 59: 169-79.
18. Castellani, S., Adams, P.M. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 1981, 73: 143-54.
19. Nabeshima, T., Yamada, K., Yamaguchi, K., Hiramatsu, M., Furukawa, H., Kameyama, T. Effect of lesions in the striatum, nucleus accumbens and medial raphe on phencyclidine-induced stereotyped behaviors and hyperactivity in rats. Eur J Pharmacol 1983, 91: 455-62.
20. Koek, W., Colpaert, F.C., Woods, J.H., Kamenka, J.M. The phencyclidine (PCP) analog N-[1-(2-benzo(B)thiophenyl) cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801. J Pharmacol Exp Ther 1989, 250: 1019-27.
21. Freed, W.J., Bing, L.A., Wyatt, R.J. Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropharmacology 1984, 23: 175-81.
22. Kitaichi, K., Yamada, K., Hasegawa, T., Furukawa, H., Nabeshima, T. Effects of risperidone on phencyclidine-induced behaviors: Comparison with haloperidol and ritanserin. Jpn J Pharmacol 1994, 66: 181-9.
23. 2A receptors. Eur J Pharmacol 1995, 280: R9-R11.
24. Schlemmer, R.F., Jackson, J.A., Preston, K.L., Bederka, J.P., Garver, D.L., Davis, J.M. Phencyclidine-induced stereotyped behavior in monkeys: Antagonism by pimozide. Eur J Pharmacol 1978, 52: 379-84.
25. Sturgeon, R.D., Fessler, R.G., London, S.F., Meltzer, H.Y. Behavioral effects of chronic phencyclidine administration in rats. Psychopharmacology 1982, 76: 52-6.
26. Nabeshima, T., Fukaya, H., Yamaguchi, K., Ishikawa, K., Furukawa, H., Kameyama, T. Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur J Pharmacol 1987, 135: 23-33.
27. Kitaichi, K., Yamada, K., Yoneda, Y. et al. Risperidone prevents the development of supersensitivity, but not tolerance to phencyclidine in rats treated with subacute phencyclidine. Life Sci 1995, 56: 531-43.
28. Sams-Dodd, F. Distinct effects of D-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol 1995, 6: 55-65.
29. Sams-Dodd, F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: A possible animal model of schizophrenia. Behav Pharmacol 1996, 7: 3-23.
30. Sams-Dodd, F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 1997, 8: 196-215.
31. Sams-Dodd, F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci Biobehav Rev 1998, 23: 287-93.
32. Qiao, H., Noda, Y., Kamei, H. et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 2001, 12: 11-5.
33. Noda, Y., Yamada, K., Furukawa, H., Nabeshima, T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: A new model of schizophrenia. Br J Pharmacol 1995, 116: 2531-7.
34. Noda, Y., Mamiya, T., Furukawa, H., Nabeshima, T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 1997, 324: 135-40.
35. Noda, Y., Kamei, H., Mamiya, T., Furukawa, H., Nabeshima, T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: Imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 2000, 23: 375-87.
36. Noda, Y., Nabeshima T. Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment. Yakugaku Zasshi 2000, 120: 677-82.
37. Nagai, T., Noda, Y., Une, T. et al. Effect of AD-5423 on animal models of schizophrenia: Phencyclidine-induced behavioral changes in mice. Neuroreport 2003, 14: 269-72.
38. Guan, H.J., Dai, J., Zhu, X.Z. Atypical antipsychotic effects of quetiapine fumarate in animal models. Acta Pharmacol Sin 2000, 21: 205-10.
39. Corbett, R., Zhou, L., Sorensen, S.M., Mondadori, C. Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology 1999, 21: S211-8.
40. Geyer, M.A., Krebs-Thomson, K., Braff, D.L., Swerdlow, N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology 2001, 156: 117-54.
41. Bakshi, V.P., Swerdlow, N.R., Geyer, M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994, 271: 787-94.
42. Bakshi, V.P., Geyer, M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995, 122: 198-201.
43. 2 receptor antagonist ketanserin. Eur J Pharmacol 1995, 287: 201-5.
44. Keith, V.A., Mansbach, R.S., Geyer, M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 1991, 30: 557-66.
45. Martinez, Z.A., Ellison, G.D., Geyer, M.A., Swerdlow, N.R. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 1999, 21: 28-39.
46. Danysz, W., Wroblewski, J.T., Costa, E. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 1988, 27: 653-6.
47. Jentsch, J.D., Tran, A., Le, D., Youngren, K.D., Phil, M., Roth, R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 1997, 17: 92-9.
48. Stefani, M.R., Moghaddam, B. Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 2002, 134: 267-74.
49. Li, Z., Kim, C.H., Ichikawa, J., Meltzer, H.Y. Effect of repeated administration of phencyclidine on spatial performance in an eight-arm radial maze with delay in rats and mice. Pharmacol Biochem Behav 2003, 75: 335-40.
50. Marquis, J.P., Goulet, S., Dore, F.Y. Schizophrenia-like syndrome inducing agent phencyclidine failed to impair memory for temporal order in rats. Neurobiol Learn Mem 2003, 80: 158-67.
51. Roullet P., Mele, A., Ammassari-Teule, M. Involvement of glutamatergic and dopaminergic systems in the reactivity of mice to spatial and non-spatial change. Psychopharmacology 1996, 126: 55-61.
52. de Lima, M.N.M., Laranja, D.C., Bromberg, E., Roesler, R., Schroder, N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 2005, 156: 139-43.
53. Mandillo, S., Rinaldi, A., Olverio, A., Mele, A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: A possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 2003, 14: 533-44.
54. Hashimoto, K., Fujita, Y., Shimizu, E., Iyo, M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 2005, 519: 114-7.
55. 1 receptors. Neuropsychopharmacology 2001, 24: 451-60.
56. Egerton, A., Reid, L., McKerchar, C.E., Morris, B.J., Pratt, J.A. Impairment in perceptual attentional set-shifting following PCP administration: A rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 2005, 179: 77-84.
57. Rodefer, J.S., Murphy, E.R., Baxter, M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 2005, 21: 1070-6.
58. 1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology 2005, 183: 190-200.
59. Deschenes, A., Goulet, S., Dore, F.Y. Rule shift under long-term PCP challenge in rats. Behav Brain Res 2006, 167: 134-40.
60. Atkins, C.M., Selcher, J.C., Petraitis, J.J., Trzaskos, J.M., Sweatt, J.D. The MAPK cascade is required for mammalian associative learning. Nat Neurosci 1998, 1: 602-9.
61. Enomoto, T., Noda, Y., Mouri, A. et al. T. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D- aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 2005, 68: 1765-74.
62. Abdul-Monim, Z., Reynolds, G.P., Neill, J.C. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 2003, 17: 57-66.
63. Idris, N.F., Repeto, P., Neill, J.C., Large, C.H. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology 2005, 179: 336-48.
64. Abdul-Monim, Z., Reynolds, G.P., Neill, J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 2006, 169: 263-73.
65. Jentsch, J.D., Taylor, J.R., Roth, R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 1998, 19: 105-13.
66. Braff, D., Stone, C., Callaway, E., Geyer, M., Glick, I., Bali, L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978, 15: 339-43.
67. Nabeshima, T., Kozawa, T., Furukawa, H., Kameyama, T. Phencyclidine-induced retrograde amnesia in mice. Psychopharmacology 1986, 89: 334-7.
68. DeNoble, V.J., Jones, K.W., Schaeffer, C.L., Bauerle, L.M. 3-((±)-2-Carboxypiperazin-4-yl) propyl-1-phosphonic acid (CPP) and phencyclidine produce a deficit of passive avoidance retention in rats. Eur J Pharmacol 1990, 175: 197-202.
69. Jentsch, J.D., Redmond, D.E., Elsworth, J.D., Taylor, J.R., Youngren, K.D., Roth, R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997, 277: 953-5.
70. Park, S., Holzman, P.S. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992, 49: 975-82.
71. Nuechterlein, K.H., Dawson, M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984, 10: 160-203.
72. Ichihara, K., Nabeshima, T., Kameyama, T. Dopaminergic agonists impair latent learning in mice: Possible modulation by noradrenergic function. J Pharmacol Exp Ther 1993, 264: 122-8.
73. Elliott, R., McKenna, P.J., Robbins, T.W., Sahakian, B.J. Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med 1995, 25: 619-30.
74. Birrell, J.M., Brown, V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 2000, 20: 4320-4.
75. Rushe, T.M., Woodruff, P.W.R., Murray, R.M., Morris, R.G. Episodic memory and learning in patients with chronic schizophrenia. Schizophr Res 1999, 35: 85-96.
76. Maren, S. Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci 2001, 24: 897-931.
77. Cochran, S.M., Kennedy, M., McKerchar, C.E., Steward, L.J., Pratt, J.A., Morris, B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: Differential modulation by antipsychotic drugs. Neuropsychopharmcology 2003, 28: 265-75.
78. Wolkin, A., Sanfilipo, M., Wolf, A.P., Angrist, B., Brodie, J.D., Rotrosen, J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992, 49: 959-65.
79. Reynolds, L.M., Cochran, S.M., Morris, B.J., Pratt, J.A., Reynolds, G.P. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetytaspartate and N-acetylaspartylglutamate in rat brain. Schizo Res 2005, 73: 147-52.
80. Olney, J.W., Labruyere, J., Price, M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244: 1360-2.
81. Ellison, G., Switzer, R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 1993, 5: 17-20.
82. Hajszan, T., Leranth, C., Roth, R.H. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry 2006, 60: 639-44.
83. Abdul-Monim, Z., Neill, J.C., Reynolds, G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 2006, Epub ahead of print.
84. Reynolds, G.P., Abdul-Monim, Z., Neill, J.C., Zhang, Z.J. Calcium binding protein markers of GABA deficits in schizophrenia - Post mortem studies and animal models. Neurotox Res 2004, 6: 57-62.
85. Beasley, C.L., Reynolds, G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizo Res 1997, 24: 349-55.
86. Hashimoto, T., Volk, D.W., Eggan, S.M. et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003, 23: 6315-26.
87. Mohn, A.R., Gainetdinov, R.R., Caron, M.G., Koller, B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98: 427-36.
88. Miyamoto, Y., Yamada, K., Noda, Y., Mori, H., Mishina, M., Nabeshima, T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon 1 subunit. J Neurosci 2001, 21: 750-7.
89. Ballard, T.M., Pauly-Evers, M., Higgins, G.A. et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 2002, 22: 6713-23.
90. Miyakawa, T., Leiter, L.M., Gerber, D.J. et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A 2003, 100: 8987-92.
91. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V. et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71: 877-92.
92. Gerlai, R., Pisacane, P., Erickson, S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res 2000, 109: 219-27.
93. Duncan, G.E., Moy, S.S., Perez, A. et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 2004, 153: 507-19.
94. Duncan, G.E., Moy, S.S., Lieberman, J.A., Koller, B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 2006, 184: 190-200.
95. Takeuchi, T., Kiyama, Y., Nakamura, K. et al. Roles of the glutamate receptor epsilon 2 and delta 2 subunits in the potentiation and prepulse inhibition of the acoustic startle reflex. Eur J Neurosci 2001, 14: 153-60.
96. Kiyama, Y., Manabe, T., Sakimura, K., Kawakami, F., Mori, H., Mishina, M. Increased thresholds for long-term potentiation and contextual learning in mice lacking the NMDA-type glutamate receptor epsilon 1 subunit. J Neurosci 1998, 18: 6704-12.
97. Moriya, T., Kouzu, Y., Shibata, S. et al. Close linkage between calcium/calmodulin kinase II alpha/beta and NMDA-2A receptors in the lateral amygdala and significance for retrieval of auditory fear conditioning. Eur J Neurosci 2000, 12: 3307-14.
98. Sakimura, K., Kutsuwada, T., Ito, I. et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon I subunit. Nature 1995, 373: 151-5.
99. Zeng, H., Chattarji, S., Barbarosie, M. et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 2001, 107: 617-29.
100. Kishimoto, Y., Kawahara, S., Mori, H., Mishina, M., Kirino, Y. Long-trace interval eyeblink conditioning is impaired in mutant mice lacking the NMDA receptor subunit epsilon 1. Eur J Neurosci 2001, 13: 1221-7.
101. Kew, J.N., Koester, A., Moreau, J.L. et al. Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J Neurosci 2000, 20: 4037-49.
102. Gerber, D.J., Hall, D., Miyakawa, T. et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A 2003, 100: 8993-8.
103. Hahn, C.G., Wang, H.Y., Cho, D.S. et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006, 12: 824-8.
104. Harrison, S.M., Reavill, C., Brown, G. et al. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci 2003, 24: 1170-9.
105. Cunningham, M.O., Hunt, J., Middleton, S. et al. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci 2006, 26: 2767-76.
106. Roberts, C., Winter, P., Shilliam, C.S. et al. Neurochemical changes in LPA1 receptor deficient mice - A putative model of schizophrenia. Neurochem Res 2005, 30: 371-7.